CMV gB Specific Neutra™ Antibody Products

Are you challenged by the complexity of cytomegalovirus (CMV) research, such as difficulties in achieving potent viral neutralization or inconsistent results in vaccine efficacy studies? Creative Biolabs' CMV gB Specific Neutra™ Antibody Products overcome these hurdles through our advanced antibody engineering and rigorous validation, empowering you to accelerate therapeutic discovery and enhance diagnostic accuracy.

Introduction to Cytomegalovirus Glycoprotein B (CMV gB)

Human cytomegalovirus (HCMV) glycoprotein B (gB) is the most abundant envelope glycoprotein and a primary antigenic determinant of the virus. It is encoded by the UL55 gene and is strictly indispensable for viral infectivity. As a critical component of the viral entry machinery, gB is highly conserved across various clinical isolates, making it an ideal candidate for universal therapeutic intervention and vaccine design.

• Structural Insights

Classified as a Class III fusion protein, gB exhibits a complex structural dynamism. It functions as a homotrimer, characterized by its ability to undergo a dramatic, irreversible conformational shift from a metastable prefusion state to a stable postfusion state. This transition provides the energy required to orchestrate the fusion of the viral envelope with the host cell membrane.

Fig.1 Schematic representation of FMDV interaction with heparan sulfate receptor.¹

• Resistance and Signaling Pathways

The role of gB extends beyond simple physical fusion; it serves as a signaling scaffold that modulates host cell environments:

1. Receptor Interaction: gB interacts with several host cell receptors, most notably the platelet-derived growth factor receptor alpha (PDGFRα), to trigger entry signaling.
2. Immune Modulation: The protein is known to influence host immune signaling, particularly by dampening type I interferon (IFN) responses, thereby facilitating viral persistence and evasion.
3. Conservation: Due to its essential nature for viral spread, gB shows limited mutational plasticity compared to other viral proteins, though its complex glycosylation patterns can pose challenges for immune recognition.

• Clinical Impact

HCMV infection remains a significant global health burden, particularly in specific populations:

1. Congenital Infection: HCMV is the leading non-genetic cause of sensorineural hearing loss and permanent neurological damage in neonates.
2. Immunocompromised Hosts: In transplant recipients and HIV/AIDS patients, HCMV reactivation is a major driver of morbidity and mortality.
3. Chronic Inflammation: Persistent infection has been implicated in cardiovascular complications and immune senescence.

• Antibodies Against CMV gB
  Antibodies targeting gB are considered the cornerstone of HCMV immunotherapy. These antibodies exert their protective effects through several distinct mechanisms:
  • Direct Neutralization: By binding to specific antigenic domains on gB (such as AD-1, AD-2, or AD-4), antibodies can sterically hinder the conformational transition from prefusion to postfusion, effectively "locking" the protein and blocking viral entry.
  • Effector Functions: Beyond direct blocking, anti-gB antibodies often mediate antibody-dependent cellular cytotoxicity (ADCC), recruiting natural killer (NK) cells to eliminate infected host cells.
  • Prophylactic and Therapeutic Potential: Current vaccine efforts utilize recombinant gB or gB-encoding DNA/mRNA to elicit high titers of neutralizing antibodies. In clinical settings, these antibodies are being developed to prevent mother-to-child transmission and to manage viral loads in transplant patients.

Applications of Anti-CMV gB Neutralizing Antibodies

Fig.2 Complement-mediated neutralization by specific gB monoclonal antibodies in MRC-5 and ARPE-19 cells.²

• Therapeutic Intervention for Transplant Patients

For immunocompromised transplant recipients, reactivation of latent HCMV poses a severe threat. Anti-CMV gB neutralizing antibodies offer a targeted therapeutic strategy. Administered prophylactically or preemptively, these antibodies can significantly reduce viral load, prevent end-organ disease, and decrease the reliance on traditional antivirals, thereby mitigating drug-related toxicity and resistance. Clinical studies underscore their role in improving patient outcomes by providing immediate, passive immunity.

• Vaccine Efficacy and Immunogenicity Assessment

In vaccine development, quantifying the titer and potency of gB-specific neutralizing antibodies is paramount. Our antibodies serve as critical reagents in standardized neutralization assays (e.g., plaque reduction neutralization tests) to evaluate vaccine-induced immune responses. They enable precise correlation between antibody levels and protective efficacy, accelerating the preclinical and clinical assessment of next-generation CMV vaccine candidates.

• Congenital CMV Infection Prevention

Preventing maternal-fetal transmission is a primary goal in congenital CMV research. High-potency anti-gB neutralizing antibodies are being investigated for passive immunization of seronegative pregnant women. By neutralizing the virus before it can cross the placental barrier, this approach holds promise for reducing the incidence and severity of congenital CMV infection and its associated long-term sequelae.

Our Anti-CMV gB Neutralizing Antibodies

Creative Biolabs delivers rigorously validated antibody tools designed for the highest standards of CMV research and development:

• High Neutralizing Potency: Antibodies are selected and engineered for exceptional neutralization efficacy against diverse clinical HCMV strains.
• Precise Epitope Targeting: Our products include antibodies targeting key functional domains of gB, crucial for blocking fusion and entry.
• Robust Validation: Each batch is extensively validated for specificity, affinity, and performance in critical applications, including neutralization assays, ELISA, Western blot, and immunofluorescence.
• Consistent Reproducibility: Guaranteed lot-to-lot consistency ensures reliable, comparable data across your entire research timeline.

With over two decades of expertise in antibody development, Creative Biolabs is your trusted partner in virology and immunology research. We combine deep scientific knowledge with cutting-edge technology to provide researchers with reliable, high-performance reagents that drive discovery forward. Our CMV gB Specific Neutra™ Antibody Products are more than just reagents; they are precision tools engineered to tackle the most challenging aspects of antiviral development. Contact our scientific team today to discuss your specific project needs and request detailed product specifications.

References

1. Burke, Heidi G., and Ekaterina E. Heldwein. "Crystal structure of the human cytomegalovirus glycoprotein B." PLoS pathogens 11.10 (2015): e1005227. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1371/journal.ppat.1005227
2. Li, Fengsheng, et al. "Complement enhances in vitro neutralizing potency of antibodies to human cytomegalovirus glycoprotein B (gB) and immune sera induced by gB/MF59 vaccination." NPJ vaccines 2.1 (2017): 36. Distributed under Open Access license CC BY 4.0, without modification. Doi: https://doi.org/10.1038/s41541-017-0038-0